Abstract:Lung cancer is the second most common cancer worldwide, accounting for 2.2 million new cases and 1.8 million deaths in 2020. Personalized targeted therapy based on actionable molecular markers has completely transformed the therapeutic landscape in NSCLC, which has improved considerably the overall survival. However, ~50% of NSCLC patients with tissue biopsy inaccessible or inadequate, limiting biomarker testing and access to targeted therapies. The availability of a wide range of highly effective targeted therapy options for NSCLC justifies the significance of developing non-invasive and cost-effective detection assays for guiding targeted therapy selection in NSCLC.Extracellular vesicles (EVs) are lipid-bilayer-enclosed vesicles of sub-micrometer size that are secreted by virtually all cell types. They contain hundreds of different proteins, thousands of intact RNA species, and double-stranded DNA (dsDNA) fragments that sample the entire human genome. Recent findings further corroborate the potential role of EVs in early cancer screening, cancer diagnosis, treatment selection and monitoring. In this study, we used lipid nanoprobe (LNP) for EV isolation from plasma and droplet digital PCR assay for detecting actionable genomic alternation to aid targeted therapy selection in NSCLC. Specifically, we extracted EV associated DNA/RNA from plasma first, and then we used the individual ddPCR assays for detecting KRAS mutations, EGFR mutations, and ALK fusions from isolated EVs associated nucleic acids, respectively. We identified KRAS mutations G12C/G12S/G13C/G12A/Q61H, EGFR L858R mutation and exon 19 deletion, and ALK-EML4 gene fusion variant 3 from 12 NSCLC patients that matched the mutation status obtained from patient tissue specimens. Only in 1 out 13 patients, EV mutation status did not match the mutation status from the tissue specimen. This data indicated that clinical actionable gene mutations are present in EVs associated nucleic acids isolated from plasma samples of NSCLC patients. We anticipate that this novel non-invasive EVs-based actionable genomic alterations detection test would efficiently assist physicians/oncologists in selecting optimal targeted therapies for cancer treatment, as recommended by National Comprehensive Cancer Network (NCCN) guidelines for NSCLC. Citation Format: Hongzhang He, Jadranka Milosevic, Siyang Zheng. Identifying actionable genomic alterations in non-small cell lung cancer through the analysis of extracellular vesicles in plasma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl) nr LB099.

Clinical Value of Extracellular Vesicles Let-7D?3p Levels in Serum of Patients with Non?small Cell Lung Carcinoma

Study of Telomerase Activity in Pleural Lavage Fluid Specimens in Patients with Non-Small-cell Lung Cancer and Its Clinical Significance

CEA, SCC and NSE levels in exhaled breath condensate--possible markers for early detection of lung cancer.

Diagnosis value of serum B7-H3 expression in non-small cell lung cancer

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

Diagnostic value of microRNA-200 expression in peripheral blood-derived extracellular vesicles in early-stage non-small cell lung cancer

Exosomal Let-7D-3p and Mir-30D-5p As Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors

Abstract LB099: Identifying actionable genomic alterations in non-small cell lung cancer through the analysis of extracellular vesicles in plasma

Diagnostic and prognostic value of serum soluble B7-H3 in nonsmall cell lung cancer

Clinical Significance of Measuring Endothelin-1 in Exhaled Breath Condensate of Patients with Non-Small Cell Lung Cancer

Analysis of Diagnostic Value of CTC and CTDNA in Early Lung Cancer

Relationship between serum VEGF, CA125, CEA, and CYFRA21-1 levels in non-small cell lung cancer patients and the clinical significance

Clinical significance of detection of p53 protein in exhaled breath condensate of patients with non-small cell lung cancer

Clinical Value and Function of Serum Mir-135B?5p Expression Levels in Patients with Renal Cell Carcinoma

To investigate the clinical value of four tumor markers in non-small cell lung cancer

Abstract 727: Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins

The diagnostic value of serum exosomal miRNA-587 combined with hypersensitive C-reactive protein as noninvasive biomarker in early-stage non-small cell lung cancer

Discovery and Validation of Extracellular Vesicle‐associated Mirnas As Noninvasive Detection Biomarkers for Early‐stage Non‐small‐cell Lung Cancer

Methods for Collection of Extracellular Vesicles and Their Content RNA as Liquid Biopsy for Lung Cancer Detection: Application of Differential Centrifugation and Annexin A5 Coated Beads

The Diagnostic and Prognostic Value of the Combination of Tumor M2-Pyruvate Kinase, Carcinoembryonic Antigen, and Cytokeratin 19 Fragment in Non-Small Cell Lung Cancer

Machine Learning-Assisted Dual-Marker Detection in Serum Small Extracellular Vesicles for the Diagnosis and Prognosis Prediction of Non-Small Cell Lung Cancer